Phosphoproteomics-Based Characterization of Prostaglandin E


Journal

Molecular pharmacology
ISSN: 1521-0111
Titre abrégé: Mol Pharmacol
Pays: United States
ID NLM: 0035623

Informations de publication

Date de publication:
05 2021
Historique:
received: 01 10 2020
accepted: 01 03 2021
pubmed: 7 3 2021
medline: 8 5 2021
entrez: 6 3 2021
Statut: ppublish

Résumé

Prostaglandin E

Identifiants

pubmed: 33674363
pii: molpharm.120.000170
doi: 10.1124/molpharm.120.000170
doi:

Substances chimiques

Proteome 0
Dinoprostone K7Q1JQR04M

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

370-382

Informations de copyright

Copyright © 2021 by The Author(s).

Déclaration de conflit d'intérêts

The authors declare no conflicts of interest.

Auteurs

Anna Mari Lone (AM)

Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital (A.M.L., K.T.) and Institute for Clinical Medicine, University of Oslo, Oslo, Norway (K.T.).

Kjetil Taskén (K)

Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital (A.M.L., K.T.) and Institute for Clinical Medicine, University of Oslo, Oslo, Norway (K.T.) kjetil.tasken@medisin.uio.no.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH